Mayne Pharma could easily reach the same revenue before metrics was sold without any debt and OPEX .The U.S. contraceptive market size was valued at around USD 8.3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 5.16% from 2023 to 2030. Increase in the use of modern contraceptives and rise in awareness among adolescents and the young population about sexual health and family planning are key factors that driving the U.S. market growth. Moreover, government programs have led to an increase in access to contraceptives that help prevent unwanted pregnancies in teenagers.
Mayne pharma have a share in more than $ 5 billion , that's only one business segment that they focused on , they sell pills , IUD and vaginal ring . That's any analysts research would expect $8.85 share price not far away
MYX Price at posting:
$3.37 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)